1201 SGN-BB228 is a first-in-class CD228-targeted costimulatory antibody anticalin<sup>®</sup> bispecific delivering potent and conditional 4–1BB costimulation to tumor-specific T cells
Crossref DOI link: https://doi.org/10.1136/jitc-2022-SITC2022.1201
Published Online: 2022-11-07
Published Print: 2022-11
Update policy: https://doi.org/10.1136/crossmarkpolicy
Heiser, Ryan
